Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

33 questions · 35 findings · 7 reviews · Oral Health · All outcomes

No studies found 9 · 25.7%GRADE not reported 16 · 45.7%Very low 5 · 14.3%Low 4 · 11.4%Moderate 1 · 2.9%High 0 · 0%

0.5% bupivacaine, 1:200,000 epinephrine vs 2% lidocaine, 1:100,000 epinephrine

Adverse effects: pain following injection · Participants of any age and gender undergoing dental procedures, and volunteers who took part in simulated scenario studies in which…

The review found no eligible studies for this question.

2 findings from 1 review

0.5% bupivacaine, 1:200,000 epinephrine vs 2% lidocaine, 1:100,000 epinephrine

Speed of onset of anaesthesia (soft tissue, simulated) · Participants of any age and gender undergoing dental procedures, and volunteers who took part in simulated scenario studies in which…

It is very uncertain whether 0.5% bupivacaine, 1:200,000 epinephrine changes speed of onset of anaesthesia (soft tissue, simulated) compared with 2% lidocaine, 1:100,000 epinephrine (very low certainty).

1 finding from 1 review

0.5% bupivacaine, 1:200,000 epinephrine vs 2% lidocaine, 1:100,000 epinephrine

Success of local anaesthesia, absence of pain (clinical testing of healthy pulps, hard and soft tissues) · Participants of any age and gender undergoing dental procedures, and volunteers who took part in simulated scenario studies in which…

0.5% bupivacaine, 1:200,000 epinephrine showed no clear difference in success of local anaesthesia, absence of pain (clinical testing of… compared with 2% lidocaine, 1:100,000 epinephrine (low certainty).

1 finding from 1 review

0.5% bupivacaine, 1:200,000 epinephrine vs 2% lidocaine, 1:100,000 epinephrine

Speed of onset of anaesthesia · Participants of any age and gender undergoing dental procedures, and volunteers who took part in simulated scenario studies in which…
1 finding from 1 review

0.5% bupivacaine, 1:200,000 epinephrine vs 2% lidocaine, 1:100,000 epinephrine

Duration of anaesthesia (soft tissue, simulated) · Participants of any age and gender undergoing dental procedures, and volunteers who took part in simulated scenario studies in which…

It is very uncertain whether 0.5% bupivacaine, 1:200,000 epinephrine changes duration of anaesthesia (soft tissue, simulated) compared with 2% lidocaine, 1:100,000 epinephrine (very low certainty).

1 finding from 1 review

0.5% bupivacaine, 1:200,000 epinephrine vs 2% lidocaine, 1:100,000 epinephrine

Speed of onset of anaesthesia (pulpal, electric pulp tester; healthy pulps) · Participants of any age and gender undergoing dental procedures, and volunteers who took part in simulated scenario studies in which…

0.5% bupivacaine, 1:200,000 epinephrine may leads to higher speed of onset of anaesthesia (pulpal, electric pulp tester; healthy… compared with 2% lidocaine, 1:100,000 epinephrine (low certainty).

1 finding from 1 review

0.5% bupivacaine, 1:200,000 epinephrine vs 2% lidocaine, 1:100,000 epinephrine

Success of local anaesthesia (pulpal, electric pulp tester; healthy pulps) · Participants of any age and gender undergoing dental procedures, and volunteers who took part in simulated scenario studies in which…

0.5% bupivacaine, 1:200,000 epinephrine showed no clear difference in success of local anaesthesia (pulpal, electric pulp tester; healthy… compared with 2% lidocaine, 1:100,000 epinephrine (low certainty).

1 finding from 1 review

0.5% bupivacaine, 1:200,000 epinephrine vs 2% lidocaine, 1:100,000 epinephrine

Success of local anaesthesia (soft tissue, self-reported; 100% success in all studies) · Participants of any age and gender undergoing dental procedures, and volunteers who took part in simulated scenario studies in which…
1 finding from 1 review
  • 'Other comparisons with 100% success': IANB - Sampaio 2012 35/35 vs 35/35; Fernandez 2005 39/39 vs 39/39. Both formulations 100% successful; no meta-analysis (no difference).
    2 studies · 74 participants
    GRADE not reported

Colchicine (0.5 mg three times per day) vs Clofazimine (100 mg daily for 30 days, then 100 mg every other day)

Complete remission, pain intensity, patient and physician evaluation · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
  • One trial at high risk of bias (de Abreu 2009) compared clofazimine (n=23) with colchicine (n=23). The number with no further aphthous episodes at 6 months was significantly greater in the clofazimine group than the…
    1 study · 46 participants
    GRADE not reported

Colchicine (0.5 mg three times per day) vs Clofazimine (100 mg daily for 30 days, then 100 mg every other day)

Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
  • Clofazimine was associated with an increase in cutaneous adverse effects (Fisher's exact test P=0.015), easily controlled; there was a greater percentage of treatment interruptions in the colchicine group due to…
    1 study · 46 participants
    GRADE not reported

Colchicine (0.5 mg three times per day) vs placebo

Complete remission (no further aphthous episodes to 6 months) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
  • The trial by de Abreu 2009 (high risk of bias) also assessed colchicine (n=23) versus placebo (n=20). The number with no further aphthous episodes at 6 months was not significantly different from placebo (Fisher's…
    1 study · 43 participants
    GRADE not reported

Colchicine (0.5 mg three times per day) vs placebo

Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
  • There was a greater percentage of treatment interruptions in the colchicine group due to gastrointestinal adverse effects (Fisher's exact test P=0.009). The review noted potential evidence of harm at a dose of 1.5 mg…
    1 study · 43 participants
    GRADE not reported

Colchicine (0.5 mg per day for 3 months) vs prednisolone

Pain at completion of treatment · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Colchicine (0.5 mg per day for 3 months) showed no clear difference in pain at completion of treatment compared with prednisolone (5 mg per day for 3 months); GRADE not reported.

1 finding from 1 review

Colchicine (0.5 mg per day for 3 months) vs prednisolone

Number of (minor aphthous) oral ulcers · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Colchicine (0.5 mg per day for 3 months) showed no clear difference in number of aphthous ulcers at completion compared with prednisolone (5 mg per day for 3 months); GRADE not reported.

1 finding from 1 review

Colchicine (0.5 mg per day for 3 months) vs prednisolone

Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review

Colchicine (0.5 mg per day for 3 months) vs prednisolone

Recurrence · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Colchicine (0.5 mg per day for 3 months) showed no clear difference in recurrence during treatment period compared with prednisolone (5 mg per day for 3 months); GRADE not reported.

1 finding from 1 review

Benzodiazepines (systemic clonazepam 0.5 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (systemic clonazepam 0.5 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review